Rifaximin
Rifaximin is a gut-selective antibiotic used to treat certain gastrointestinal conditions, including travellers’ diarrhoea caused by susceptible non-invasive Escherichia coli, hepatic encephalopathy, and irritable bowel syndrome with diarrhoea (IBS-D), depending on local approval. It works by inhibiting bacterial DNA-dependent RNA polymerase, reducing the growth of susceptible bacteria within the intestine. It is available as oral tablets and, in some markets, oral suspension. Common side effects include nausea, abdominal pain, bloating, headache, and diarrhoea. Important precautions include the possibility of antibiotic-associated diarrhoea, including Clostridioides difficile infection, and limited effectiveness against invasive infections or diarrhoea accompanied by fever or blood in the stool. Rifaximin should be used under medical supervision, with the indication and treatment duration determined by the patient’s condition and local prescribing guidance.
Rifaximin was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Rifaximin, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Rifaximin from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Rifaximin, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
